High dose titration of calcium channel blocking agents for primary pulmonary hypertension: guidelines for short-term drug testing

Department of Medicine, University of Illinois College of Medicine, Chicago.

Forty-seven patients with primary pulmonary hypertension were evaluated with a dose titration protocol utilizing nifedipine (20 mg orally) or diltiazem (60 mg orally) given every hour until maximal effectiveness was achieved. Of the patients tested, 15 (32%) had a greater than 20% reduction in pulmonary artery pressure (mean 36.2 +/- 8%, p less than 0.01) and pulmonary vascular resistance (mean 50.2 +/- 7%, p less than 0.01) (pressure responders). Nineteen (40%) had a greater than 20% reduction in pulmonary vascular resistance (mean 25.2 +/- 12%, p less than 0.01), with less than a 20% decrease in pulmonary artery pressure (resistance responders). Ten had no significant change in pulmonary artery pressure or pulmonary vascular resistance (nonresponders), and three were unable to tolerate the calcium channel blocking agents. No hemodynamic profile allowed prediction of the type of response to these agents. No mortality or serious morbidity was associated with the drug testing. These findings indicate that calcium channel blockers, when titrated to maximally effective doses, may cause substantial reductions in pulmonary artery pressure and pulmonary vascular resistance in patients with primary pulmonary hypertension. Testing with hemodynamic monitoring is necessary to ascertain which patients will respond. Patients with primary pulmonary hypertension are able to tolerate short-term administration of high doses of calcium channel blockers.

This article has been cited by other articles:

				National Pulmonary Hypertension Centres of the UK Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland Heart, March 1, 2008; 94(Suppl_1): i1 - i41. [Full Text] [PDF]

				National Pulmonary Hypertension Centres of the UK Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland Thorax, March 1, 2008; 63(Suppl_2): ii1 - ii41. [Full Text] [PDF]

				O. Sitbon, M. Humbert, X. Jais, V. Ioos, A. M. Hamid, S. Provencher, G. Garcia, F. Parent, P. Herve, and G. Simonneau Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension Circulation, June 14, 2005; 111(23): 3105 - 3111. [Abstract] [Full Text] [PDF]

				Task Force members, N. Galie, A. Torbicki, R. Barst, P. Dartevelle, S. Haworth, T. Higenbottam, H. Olschewski, A. Peacock, G. Pietra, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology Eur. Heart J., December 2, 2004; 25(24): 2243 - 2278. [Full Text] [PDF]

				E. Bossone, G. Paciocco, D. Iarussi, A. Agretto, A. Iacono, B. W. Gillespie, and M. Rubenfire The Prognostic Role of the ECG in Primary Pulmonary Hypertension Chest, February 1, 2002; 121(2): 513 - 518. [Abstract] [Full Text] [PDF]

				G. Paciocco, F.J. Martinez, E. Bossone, E. Pielsticker, B. Gillespie, and M. Rubenfire Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension Eur. Respir. J., April 1, 2001; 17(4): 647 - 652. [Abstract] [Full Text] [PDF]

				R. V. AGUILAR and H. W. FARBER Epoprostenol (Prostacyclin) Therapy in HIV-associated Pulmonary Hypertension Am. J. Respir. Crit. Care Med., November 1, 2000; 162(5): 1846 - 1850. [Abstract] [Full Text]

				A J Peacock Rare diseases bullet 5: Primary pulmonary hypertension Thorax, December 1, 1999; 54(12): 1107 - 1118. [Full Text]

				M. A. Alpert, M. D. Concannon, B. Mukerji, and V. Mukerji Pharmacotherapy of Chronic Pulmonary Arterial Hypertension: Value and Limitations: Part I: Primary Pulmonary Hypertension Angiology, August 1, 1994; 45(8): 667 - 676. [Abstract] [PDF]

				J. Partanen, M. S. Nieminen, K. Luomanmaki, and S. Rich Death in a Patient with Primary Pulmonary Hypertension after 20 mg of Nifedipine N. Engl. J. Med., September 9, 1993; 329(11): 812 - 813. [Full Text]